Taken together, loss of Nedd9 remarkably delayed CLL onset and progression in vivo, particularly impaired CLL cell infiltration in lymphoid organs, leading to a substantial survival advantage in mice. Here, NEDD9 is linked to B-cell chronic lymphocytic leukemia.